Clinical Development │ Clinical Development │ R&D │ NIPPON SHINYAKU CO., LTD.

Clinical Development

Disclaimer (Please read when viewing this page)

This page contains an overview of the clinical trials conducted by Nippon Shinyaku. The purpose of this page is to widely provide information on ongoing clinical trials to the general public, including patients and their families, and is not intended to advertise or promote our products.

The information posted here is based on data publicly available in the clinical trial registries such as jRCT and ClinicalTrials.gov For detailed information on the clinical trials conducted or being conducted by Nippon Shinyaku, please check the link to each clinical trial registries.

Please note that the information posted here may differ from the latest information depending on the timing of updates.

Ongoing Clinical Trial

Stage	Indications	Code No. (Generic name)	Study No.	Recruitment status	Link to Clinical Trial Registries
Stage	Indications	Code No. (Generic name)	Study No.	Recruitment status	jRCT	ClinicalTrials.gov
Phase II	Eosinophilic granulomatosis with polyangiitis	NS-229	NS229-P2-01	Recruiting	jRCT2031230526	NCT06046222
Phase II	Duchenne muscular dystrophy	NS-089/NCNP-02 (brogidirsen)	NS089/NCNP02-P2OE	Recruiting	jRCT2041250028	NCT05996003
Phase IV	Pediatric pulmonary arterial hypertension	NS-304 (selexipag)	NS304P-P2-1	Not Recruiting	jRCT2080225295	－
Phase II	Arteriosclerosis obliterans	NS-304 (selexipag)	NS304A-P2-3	Not Recruiting	jRCT2031210497	－
Phase II	Duchenne muscular dystrophy	NS-089/NCNP-02 (brogidirsen)	NS089/NCNP02-P2OE	Not Recruiting	jRCT2031210162	NCT05135663
Phase I/II	Blastic plasmacytoid dendritic cell neoplasm	NS-401 (tagraxofusp)	NS401-P1-02	Not Recruiting	jRCT2031220023	－
Phase I/II	Duchenne muscular dystrophy	NS-050/NCNP-03	NS-050/NCNP-03-101	Recruiting	jRCT2041240060	NCT06053814
Phase I	Acute myeloid leukemia	NS-917 (radgocitabine)	NS917-P1-01	Recruiting	jRCT2031210452	－
Phase I	Healthy volunteer	NS-863	NS863-P1-02	Recruiting	jRCT2071240098	－
Phase I	Healthy volunteer	NS-025	NS025-P1-02	Not Recruiting	jRCT2031240632	－
Phase I	Healthy volunteer	NS-229	NS229-P1-04	Not Recruiting	jRCT2071240058	－
Phase I	Healthy volunteer	NS-229	NS229-P1-03	Pending	jRCT2071240076	－

Completed Clinical Trial

Stage	Indications	Code No. (Generic name)	Study No.	Recruitment status	Link to Clinical Trial Information databases
Stage	Indications	Code No. (Generic name)	Study No.	Recruitment status	jRCT	ClinicalTrials.gov
Phase I	Healthy volunteer	NS-580	NS580-P1-04	Complete	jRCT2071220031	－
Phase I	Healthy volunteer	NS-580	NS580-P1-05	Complete	jRCT2071220011	－
Phase I	Healthy volunteer	NS-580	NS580-P1-06	Complete	－	NCT06670898
Phase I	Healthy volunteer	NS-229	NS229-P1-02	Complete	jRCT2051210094	－
Phase I	Healthy volunteer	NS-863	NS863-P1-01	Complete	jRCT2071230038	－
Phase I	Healthy volunteer	NS-025	NS025-P1-01	Complete	jRCT2031220474	－
Phase I	Healthy volunteer	NS-161	NS161-P1-01	Complete	jRCT2071220066	－
Phase I/II	Acute myeloid leukemia	NS-87 (daunorubicin/cytarabine)	NS87-P1-2	Complete	jRCT2080224810	－
Phase II	Endometriosis	NS-580	NS580-P2-02	Complete	jRCT2031210685	－
Phase II	Chronic prostatitis/chronic pelvic pain syndrome	NS-580	NS580C-P2-01	Complete	jRCT2031230134	－
Phase III	Duchenne muscular dystrophy	NS-065/NCNP-01 (viltolarsen)	NS-065/NCNP-01-301	Complete	jRCT2080224893	NCT04060199

Clinical Development

Clinical Development

Disclaimer (Please read when viewing this page)

Related Link